WASHINGTON (MedPage Today) — Medicare providers deemed at a “high risk” of defrauding the government could be fingerprinted and undergo background checks, according to new regulations proposed Monday by the Centers for Medicare and Medicaid Services (CMS).
No Comments »
Filed under: General Health News
Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, today announced that seven abstracts related to two of the company’s cardiac Positron Emission Tomography (PET) imaging candidates will be presented at ASNC2010, the 15th Annual Scientific Session of the American Society of Nuclear Cardiology, being held September 23-26, 2010 in Philadelphia.
No Comments »
Filed under: Pharmacy News
Celldex Therapeutics, Inc. today announced that the first patient has been treated in a randomized Phase 2b study of the Company’s CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. CDX-011 targets the protein GPNMB, which is over expressed in a variety of cancers including breast cancer, melanoma, [...]
No Comments »
Filed under: Pharmacy News
Micromet, Inc. today announced the initiation of a phase 2 trial of the Company’s lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE antibodies, designed to harness the body’s T cells to kill cancer cells.
No Comments »
Filed under: Pharmacy News
Bristol-Myers Squibb Company and AstraZeneca today announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in glycosylated hemoglobin levels (HbA1c) in adult patients with type 2 diabetes compared to glimepiride alone.
No Comments »
Filed under: Pharmacy News
Sanofi-aventis announced today results of two studies presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.
No Comments »
Filed under: Pharmacy News
Sanofi-aventis announced today the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden.
No Comments »
Filed under: Pharmacy News
Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced key findings from preclinical studies of the Company’s novel cancer metabolism inhibitor (CMI), MPC-9528, at the Cancer and Metabolism Pathways to the Future Symposium in Edinburgh, Scotland.
No Comments »
Filed under: Pharmacy News
Chelsea Therapeutics International, Ltd. announced that preliminary analyses of its Phase III NORTHERA™ Study 301 met its primary endpoint. Treatment with Northera provided clinically meaningful and statistically significant improvement.
No Comments »
Filed under: Pharmacy News
Boston Scientific Corporation is to acquire Athmatx. Inc, from Synnyvale, California for an upfront payment of $193.5 million plus additional payments of up to $250 million. Boston Scientific says it has just signed a definitive merger agreement with Athmatx…
No Comments »
Filed under: Pharmacy News
